Roche News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

19.12.24	Roche’s Phase IIb study of prasinezumab missed primary endpoint, but suggests possible benefit in early-stage Parkinson’s disease (Roche Holding AG)
19.12.24	Roche’s Phase IIb study of prasinezumab missed primary endpoint, but suggests possible benefit in early-stage Parkinson’s disease (GlobeNewswire)
18.12.24	Roche transforms mass spectrometry diagnostics with launch of cobas® Mass Spec solution (GlobeNewswire)
18.12.24	Roche transforms mass spectrometry diagnostics with launch of cobas® Mass Spec solution (Roche Holding AG)
13.12.24	Roche’s Vabysmo prefilled syringe (PFS) approved in the EU for three retinal conditions that can cause blindness (GlobeNewswire)
13.12.24	Roche receives CE Mark for new and updated molecular cobas 6800/8800 systems, enhancing laboratory efficiency and testing capabilities (Roche Holding AG)
13.12.24	Roche receives CE Mark for new and updated molecular cobas 6800/8800 systems, enhancing laboratory efficiency and testing capabilities (GlobeNewswire)
10.12.24	New and updated data for Roche's fixed-duration Columvi and Lunsumio at ASH 2024 reinforce their potential to improve outcomes for people with lymphoma (Roche Holding AG)
10.12.24	New and updated data for Roche's fixed-duration Columvi and Lunsumio at ASH 2024 reinforce their potential to improve outcomes for people with lymphoma (GlobeNewswire)
09.12.24	Roche commences tender offer for all shares of Poseida Therapeutics, Inc. for $9.00 per share in cash, plus a non-tradeable contingent value right for up to $4.00 per share in cash (Roche Holding AG)
09.12.24	Roche commences tender offer for all shares of Poseida Therapeutics, Inc. for $9.00 per share in cash, plus a non-tradeable contingent value right for up to $4.00 per share in cash (GlobeNewswire)
08.12.24	Five-year results confirm Roche’s Polivy combination therapy as new standard of care for previously untreated aggressive lymphoma (GlobeNewswire)
08.12.24	Five-year results confirm Roche’s Polivy combination therapy as new standard of care for previously untreated aggressive lymphoma (Roche Holding AG)
05.12.24	FDA accepts supplemental Biologics License Application for Roche’s Columvi combination for people with relapsed or refractory diffuse large B-cell lymphoma (GlobeNewswire)
05.12.24	FDA accepts supplemental Biologics License Application for Roche’s Columvi combination for people with relapsed or refractory diffuse large B-cell lymphoma (Roche Holding AG)
26.11.24	Roche enters into a definitive agreement to acquire Poseida Therapeutics, including cell therapy candidates and related platform technologies (GlobeNewswire)
26.11.24	Roche enters into a definitive agreement to acquire Poseida Therapeutics, including cell therapy candidates and related platform technologies (Roche Holding AG)
26.11.24	Roche reports update on Phase III SKYSCRAPER-01 study results (GlobeNewswire)
26.11.24	Roche reports update on Phase III SKYSCRAPER-01 study results (Roche Holding AG)
05.11.24	Roche to present new and encouraging long-term follow-up data across broad haematology portfolio at ASH 2024 (Roche Holding AG)
05.11.24	Roche to present new and encouraging long-term follow-up data across broad haematology portfolio at ASH 2024 (GlobeNewswire)
31.10.24	Roche presents new data at CTAD, demonstrating its growing momentum in diagnostics for Alzheimer’s disease (Roche Holding AG)
31.10.24	Roche presents new data at CTAD, demonstrating its growing momentum in diagnostics for Alzheimer’s disease (GlobeNewswire)
31.10.24	New England Journal of Medicine publishes landmark phase III results for Roche’s Itovebi, showing more than doubling of progression-free survival in certain type of HR-positive advanced breast cancer (Roche Holding AG)
31.10.24	New England Journal of Medicine publishes landmark phase III results for Roche’s Itovebi, showing more than doubling of progression-free survival in certain type of HR-positive advanced breast cancer (GlobeNewswire)
23.10.24	[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong sales growth of 9% (CER) continues in the third quarter of 2024; Group sales increase 6% in the first nine months (Roche Holding AG)
23.10.24	[Ad hoc-Mitteilung gemäss Art. 53 KR] Starkes Verkaufswachstum der Roche-Gruppe von 9% (CER) auch im dritten Quartal 2024; Konzernverkäufe steigen in den ersten neun Monaten um 6% (GlobeNewswire)
23.10.24	[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong sales growth of 9% (CER) continues in the third quarter of 2024; Group sales increase 6% in the first nine months (GlobeNewswire)
18.10.24	Roche’s Vabysmo improved vision in underrepresented populations with diabetic macular edema (DME) in a first-of-its-kind study (Roche Holding AG)
18.10.24	Roche’s Vabysmo improved vision in underrepresented populations with diabetic macular edema (DME) in a first-of-its-kind study (GlobeNewswire)
14.10.24	Majority of children with spinal muscular atrophy (SMA) treated with Roche’s Evrysdi are able to sit, stand and walk independently, two-year data demonstrate (Roche Holding AG)
14.10.24	Majority of children with spinal muscular atrophy (SMA) treated with Roche’s Evrysdi are able to sit, stand and walk independently, two-year data demonstrate (GlobeNewswire)
11.10.24	FDA approves Roche’s Itovebi, a targeted treatment for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation (Roche Holding AG)
11.10.24	FDA approves Roche’s Itovebi, a targeted treatment for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation (GlobeNewswire)
10.10.24	Roche obtains CE certification for the first companion diagnostic to identify patients with gastric and gastroesophageal junction cancer eligible for targeted treatment with VYLOY (Roche Holding AG)
10.10.24	Roche obtains CE certification for the first companion diagnostic to identify patients with gastric and gastroesophageal junction cancer eligible for targeted treatment with VYLOY (GlobeNewswire)
26.09.24	Positive phase III results for Roche’s Gazyva/Gazyvaro show superiority to standard therapy alone in people with lupus nephritis (GlobeNewswire)
26.09.24	Positive phase III results for Roche’s Gazyva/Gazyvaro show superiority to standard therapy alone in people with lupus nephritis (Roche Holding AG)
24.09.24	Roche launches the first test to use its breakthrough TAGS technology for high throughput, simultaneous detection of 12 respiratory viruses (GlobeNewswire)
24.09.24	Roche launches the first test to use its breakthrough TAGS technology for high throughput, simultaneous detection of 12 respiratory viruses (Roche Holding AG)
23.09.24	WHO endorses dual-stain cytology (CINtec PLUS) testing in its cervical cancer prevention guidelines, advancing patient care and underlining Roche’s role in pioneering cervical cancer solutions (GlobeNewswire)
23.09.24	WHO endorses dual-stain cytology (CINtec PLUS) testing in its cervical cancer prevention guidelines, advancing patient care and underlining Roche’s role in pioneering cervical cancer solutions (Roche Holding AG)
19.09.24	Positive phase III results show Xofluza significantly reduces the transmission of influenza viruses (GlobeNewswire)
19.09.24	Positive phase III results show Xofluza significantly reduces the transmission of influenza viruses (Roche Holding AG)
16.09.24	FDA approves OCREVUS ZUNOVO™ as the first and only twice-a-year 10-minute subcutaneous injection for people with relapsing and progressive multiple sclerosis (Roche Holding AG)
16.09.24	FDA approves OCREVUS ZUNOVO™ as the first and only twice-a-year 10-minute subcutaneous injection for people with relapsing and progressive multiple sclerosis (GlobeNewswire)
13.09.24	FDA approves Roche’s Tecentriq Hybreza, the first and only subcutaneous anti-PD-(L)1 cancer immunotherapy (GlobeNewswire)
13.09.24	FDA approves Roche’s Tecentriq Hybreza, the first and only subcutaneous anti-PD-(L)1 cancer immunotherapy (Roche Holding AG)
10.09.24	Roche eröffnet Pharmaforschungs- und Entwicklungszentrum in Basel, um wissenschaftliche Innovationen zu beschleunigen (GlobeNewswire)
10.09.24	Roche opens Pharma Research and Development Center in Basel to accelerate scientific innovation (GlobeNewswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Givaudan	3’904.00	-0.08 %	K V
Roche Hldg G	245.50	-0.49 %	K V
Novartis	86.47	-0.65 %	K V
Sonova Hldg	290.80	-0.68 %	K V
Kuehne+Nagel Int	200.90	-0.69 %	K V
Swiss Re	127.20	-1.47 %	K V
Sika	214.80	-1.74 %	K V
Part Grp Hldg	1’195.00	-1.81 %	K V
Holcim	85.40	-1.82 %	K V
UBS Group	26.37	-1.93 %	K V

mehr

11:04		Wechsel bei Sanofi: Ex-Morphosys-Chef Kress tritt in den Verwaltungsrat ein -Sanofi-Aktie tiefer
10:02		DAX 40-Wert Bayer-Aktie: So viel Verlust hätte ein Bayer-Investment von vor einem Jahr eingebracht
09:28		Angespannte Stimmung in Europa: STOXX 50 legt zum Handelsstart den Rückwärtsgang ein
09:28		Freitagshandel in Frankfurt: LUS-DAX beginnt Handel mit Verlusten
09:28		Schwacher Wochentag in Zürich: SMI startet mit Verlusten
09:28		Schwacher Handel in London: FTSE 100 beginnt die Freitagssitzung im Minus
09:28		Handel in Zürich: SPI zum Handelsstart in der Verlustzone
09:28		Schwache Performance in Frankfurt: TecDAX verbucht zum Handelsstart Verluste

11:04

Wechsel bei Sanofi: Ex-Morphosys-Chef Kress tritt in den Verwaltungsrat ein -Sanofi-Aktie tiefer

10:02

DAX 40-Wert Bayer-Aktie: So viel Verlust hätte ein Bayer-Investment von vor einem Jahr eingebracht

09:28

Angespannte Stimmung in Europa: STOXX 50 legt zum Handelsstart den Rückwärtsgang ein

09:28

Freitagshandel in Frankfurt: LUS-DAX beginnt Handel mit Verlusten

09:28

Schwacher Wochentag in Zürich: SMI startet mit Verlusten

09:28

Schwacher Handel in London: FTSE 100 beginnt die Freitagssitzung im Minus